-
- Posted Monday July 15, 2013
TGen President Dr. Jeffrey Trent speaks at Brookings Institution biomedical conference
Dr. Trent presents TGen's precision medicine research at the world's most influential think tank
WASHINGTON, D.C. - July 15, 2013 - Dr. Jeffrey
Trent, President and Research Director for the Translational
Genomics Research Institute (TGen), will discuss state-of-the-art
genomics research July 16 at the Brookings Institution.
Dr. Trent, Ph.D., F.A.C.M.G., and former Scientific Director of
the National Human Genome Research Institute, is part of a panel,
Innovation in Action, at Brookings' 2nd annual State of
Biomedical Innovation Conference, which will focus on the use of
novel data sources to improve medical product development and care
delivery.
Specifically, Dr. Trent will discuss TGen's ongoing work in
translating genomics research into clinical benefit. TGen is one of
a very few centers who are using the entire human genome in
clinical trials in order to diagnose or make treatment decisions
for an individual patient (precision medicine).
"The human genome will be the medical textbook for the next
century and beyond," Dr. Trent said. "By harnessing the power of
the human genome, we will provide immeasurable patient benefit
while at the same time reducing the time and costs of diagnosis and
treatment. TGen is a global leader in clinical trials that deploy
this form of innovative research."
TGen's translational model enables pioneering discoveries in the
laboratory to be quickly moved to clinical trials where they can be
used to immediately benefit patients with many types of cancer and
other debilitating diseases.
Dr. Trent's panel will be moderated by Dr. Mark B. McClellan,
Director and Fellow of Brookings' Initiative on Innovation and
Value in Health Care. He is the former administrator for the
Centers for Medicare and Medicaid Services (2004-2006), and the
former commissioner of the Food and Drug Administration
(2002-2004). He also served as a member of the President's Council
of Economic Advisers, and as senior director for health care policy
at the White House (2001-2002). In these positions, he developed
and implemented major reforms in health policy.
This conference is being convened by the Engelberg Center for
Health Care Reform at Brookings, which was established to help turn
ideas for health care reform into action, including reducing gaps
in insurance coverage and ensuring health care affordability. Its
mission is to develop data-driven, practical policy solutions that
promote broad access to high-quality, affordable and innovative
care in the United States. The Center also conducts research, makes
policy recommendations, and facilitates development of new
consensus around key issues, providing technical support to
implement and evaluate new solutions in collaboration with a broad
range of stakeholders.
The conference is scheduled for 9 a.m.-12:30 p.m. EDT July 16 at
the Brookings Institution, Falk Auditorium, 1775 Massachusetts
Avenue, N.W., Washington, D.C. Dr. Trent's hour-long panel is
scheduled to start at 10:10 a.m. The event will be streamed
live on the Brookings website:
http://www.brookings.edu/events/2013/07/16-biomedical-innovation.
# # #
About the Brookings Institution
The Brookings Institution is a nonprofit public policy
organization based in Washington, DC. Our mission is to conduct
high-quality, independent research and, based on that research, to
provide innovative, practical recommendations that advance three
broad goals: strengthen American democracy; foster the economic and
social welfare, security and opportunity of all Americans; and
secure a more open, safe, prosperous and cooperative international
system. Brookings is proud to be consistently ranked as the most
influential, most quoted and most trusted think tank. More
information: www.brookings.edu.
About TGen
Translational Genomics Research Institute (TGen) is a Phoenix,
Arizona-based non-profit organization dedicated to conducting
groundbreaking research with life changing results. TGen is focused
on helping patients with cancer, neurological disorders and
diabetes, through cutting edge translational research (the process
of rapidly moving research towards patient benefit). TGen
physicians and scientists work to unravel the genetic components of
both common and rare complex diseases in adults and children.
Working with collaborators in the scientific and medical
communities literally worldwide, TGen makes a substantial
contribution to help our patients through efficiency and
effectiveness of the translational process. For more information,
visit:www.tgen.org.
Press Contact:
Steve Yozwiak
TGen Senior Science Writer
602-343-8704
[email protected]
